在接受GLP-1主动剂治疗的患者中,X光中脸部体积变化
Rahul K Sharma1, Kelly L Vittetoe1, Alexander J Barna1
1Vanderbilt University Medical Center, Division of Facial Plastic and Reconstructive Surgery, Nashville, Tennessee, USA.
概括
减肥药物,如塞马格卢提德,可以导致面部膨胀,通常被称为"Ozempic face. 患者平均每减掉10公斤,就会失去7%的面部中部体积,主要来自表面的脂肪.
科学领域:
- 整形外科 整形外科 整形外科
- 医疗成像医学成像
- 药理学 药理学是指药理学的学科.
背景情况:
- 面部整形外科医生观察到面部膨胀和过早衰老的患者数量增加,这可能与塞马格卢提德的使用有关.
- 目前没有客观数据可以量化与这种减肥药物相关的中脸体积损失.
研究的目的:
- 在使用类似葡萄糖-1 (GLP-1) 激动剂的患者中量化评估中面体积变化.
- 为了研究体重减轻和面部体积减少的程度之间的相关性.
主要方法:
- 一个单一的高等学术医学中心的回顾性队列研究.
- 2017-2024年对接受GLP-1激动剂的患者的电子病历和头部/部成像 (CT/MR) 分析.
- 测量总体,表面和深层中表面体积的变化,并对体重减轻的相关性进行统计分析.
主要成果:
- 包括20名患者,在321天内平均体重减轻11.0公斤.
- 面部中部总体积的中位数下降了9.0%,表面体积下降了11.0%,深部体积下降了7.0%.
- 在体重减轻和表面体积减轻之间发现了显著的相关性 (rho=0.590,P=0.006). 线性回归表明,每10公斤体重减轻,面部中部体积损失为7%.
结论:
- 患者可以预计,每10公斤体重损失,面部中部体积损失约为7%,主要影响表面脂肪.
- 这项研究为"Ozempic face"现象提供了早期的定量证据,突出了GLP-1激素治疗导致的面部体积变化.
相关概念视频
01:24Glucagon-like Receptor Agonists
443
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
443
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:06Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
313
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
313
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278